NEW YORK (GenomeWeb News) – Venaxis today priced the public offering of about 8.3 million shares of its common stock at $2.40 per share.

Net proceeds from the offering are expected at around $18.4 million, which the Castle Rock, Colo.-based firm will use for working capital and other corporate purposes, including the sales and marketing of its APPY1 appendicitis test in the European Union, and development efforts to expand and improve the test's performance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.